Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: C. Difficile Infection Clear all
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

NCT01232595
View directory record Official record
Conditions
Moderate Clostridium Difficile Infection
Interventions
LFF571, Vancomycin (POC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 25, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

NCT03244644
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
60
States / cities
Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 25, 2026, 4:48 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

NCT07221708
View directory record Official record
Conditions
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Interventions
Vancomycin (POC)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
65 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Glen Burnie, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 4:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplant for Primary CDI

NCT03795233
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal microbiota transplant G3 capsules, Oral Vancomycin alone
Biological · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 25, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

NCT03617445
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 25, 2026, 4:48 AM EDT
Completed No phase listed Observational

Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes

NCT00446355
View directory record Official record
Conditions
Clostridium Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2009 · Synced Sep 25, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 25, 2026, 4:48 AM EDT
Completed Phase 3 Interventional

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

NCT00106509
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions
tolevamer potassium-sodium (GT267-004)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
99
States / cities
Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Sep 25, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI

NCT02255305
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
FMT, Antimicrobials
Biological · Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 25, 2026, 4:48 AM EDT
Not listed Phase 2 Interventional

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

NCT03988855
View directory record Official record
Conditions
Clostridium Difficile (C. Difficile)
Interventions
DNV3837
Drug
Lead sponsor
Deinove
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Anniston, Alabama • Sacramento, California • Idaho Falls, Idaho + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 25, 2026, 4:48 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

NCT03005379
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbiota Therapy (FMT), Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 25, 2026, 4:48 AM EDT
Terminated Phase 3 Interventional Results available

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

NCT04802837
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ridinilazole, Vancomycin
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 25, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

NCT01925417
View directory record Official record
Conditions
Recurrent Clostridium Difficile Infection
Interventions
RBX2660 (microbiota suspension)
Biological
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 25, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT03788434
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions
VE303, Placebo
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 25, 2026, 4:48 AM EDT
Recruiting Not applicable Interventional

Lifestyle and Recurrent Clostridioides Difficile Infection (CDI)

NCT07613645
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Health counseling sessions, Diet (control diet), Diet (experimental diet)
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 25, 2026, 4:48 AM EDT
Recruiting Not applicable Interventional

Fecal Microbiota Transplantation for C Diff Infection

NCT01905709
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Human fecal matter
Biological
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 25, 2026, 4:48 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

NCT05153499
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
CP101, Placebo
Biological · Other
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
61
States / cities
Phoenix, Arizona • Mission Hills, California • Oakland, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 25, 2026, 4:48 AM EDT
Completed Phase 4 Interventional

Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial

NCT02462590
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Infections, C-Difficile, Antibiotic-associated Diarrhea, Diarrhea
Interventions
L. rhamnosus GG - Probiotic, Placebo - Microcrystalline Cellulose
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 25, 2026, 4:48 AM EDT
Recruiting Not applicable Interventional

Pre-emptive Prevention for Patients at High Risk for Hospital-onset Clostridioides Difficile

NCT05389904
View directory record Official record
Conditions
C. Difficile
Interventions
Arm 1: Routine care, Arm 2: Preemptive C. difficile infection prevention bundle
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 25, 2026, 4:48 AM EDT
Not yet recruiting Early Phase 1 Interventional

Pilot Trial of Xylitol for C. Difficile De-Colonization in Patients With Inflammatory Bowel Disease

NCT06799039
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Clostridioides Difficile Infection
Interventions
Xylitol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 25, 2026, 4:48 AM EDT
Completed Phase 3 Interventional Results available

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

NCT03182907
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Year to 17 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 25, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)

NCT03298048
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
Low fecal microbiota dose, Mid fecal microbiota dose, High fecal microbiota dose
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 25, 2026, 4:48 AM EDT
Completed Early Phase 1 Interventional

Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis

NCT03268213
View directory record Official record
Conditions
Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
Interventions
Fecal Microbial Transplantation
Biological
Lead sponsor
Stony Brook University
Other
Eligibility
7 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 25, 2026, 4:48 AM EDT
Completed No phase listed Observational

Protocol for Admission Toxigenic C. Difficile Surveillance

NCT04014608
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Standard Practice to Prevent Hospital Onset CDI
Other
Lead sponsor
Endeavor Health
Other
Eligibility
Up to 1 Year
Enrollment
148,549 participants
Timeline
2016 – 2018
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 25, 2026, 4:48 AM EDT